Zomedica Q1 revenue $3.8M, up 38% pro forma; net loss $3.9M

Zomedica Corp.

2022-Q1 EPS reported -$0.00 revenue$3,751,000

Revenue $3.8M (74% gross margin) vs $14K in Q1 2021; up 38% over combined Zomedica+PulseVet $2.7M.
PulseVet revenue $3.7M (+36% vs standalone Q1 2021); small animal unit sales 30 (+500% YoY).
TRUFORMA product revenue $57K (+307% vs $14K); launched endogenous ACTH assay in April 2022.
Cash $192.3M at quarter end; net loss $3.9M ($0.004/share) vs $36.0M loss in Q1 2021.
SG&A $6.7M (+91% YoY) driven by share-based comp and sales force expansion; R&D $351K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.